Tarsus Pharmaceuticals (TARS) Common Equity (2019 - 2026)

Tarsus Pharmaceuticals' Common Equity history runs 8 years deep, the most recent figure standing at $349.0 million for Q1 2026.

• In Q1 2026, Common Equity rose 1.9% year-over-year to $349.0 million; the TTM figure through Mar 2026 stood at $349.0 million (up 1.9% YoY), while the FY2025 annual figure was $343.4 million, up 52.95% from the prior year.
• Common Equity for Q1 2026 stood at $349.0 million, up from $343.4 million in the prior quarter.
• The five-year high for Common Equity was $349.0 million in Q1 2026, with the low at $147.7 million in Q2 2023.
• The 5-year median for Common Equity is $224.5 million (2024), against an average of $246.5 million.
• The sharpest annual moves came in 2023 and 2024: Common Equity plunged 33.31% in 2023, then surged 70.75% in 2024.
• Tarsus Pharmaceuticals' Common Equity stood at $192.9 million in 2022, then gained by 2.12% to $197.0 million in 2023, then gained by 13.98% to $224.5 million in 2024, then jumped by 52.95% to $343.4 million in 2025, then advanced by 1.61% to $349.0 million in 2026.
• Business Quant data shows TARS's Common Equity at $349.0 million in Q1 2026, $343.4 million in Q4 2025, and $335.1 million in Q3 2025.